- Article
Adverse Reactions to Evolocumab: Analysis of Real-World Data from EudraVigilance
- Fabrizio Calapai,
- Carmen Mannucci,
- Mariaconcetta Currò,
- Luigi Cardia,
- Emanuela Esposito,
- Gioacchino Calapai and
- Ilaria Ammendolia
Background: Evolocumab is a humanized immunoglobulin G2 monoclonal antibody, directed against Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9), prescribed in hypercholesterolemic patients. The safety profile of this drug is currently defined by...